Tag: PARP Inhibitor
Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males
August 12, 2024 9:00 amby Jax DiEugenio
Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more
ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer
March 20, 2024 9:00 amClearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more
Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer
February 21, 2024 9:00 amBy Mark Fuerst
About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more
Ovarian Cancer: Best Practices for Managing PARP Inhibitor Side Effects
October 4, 2023 9:00 amOncologists treating ovarian cancer need to be proactive to prevent or reduce the likelihood of adverse effects associated with poly (ADP-ribose) polymerase (PARP) inhibitors, noted authors of a review in the ASCO Educational Book.
William Tew, MD, of Memorial Sloan … Read more
DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors
June 7, 2023 6:55 amKey Points:
- Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
- T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer
June 3, 2023 7:02 amKey takeaways:
- Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
- The relative contribution of durvalumab requires further study.
CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more
Tumor Testing May Be Increasingly Useful in Ovarian Cancer
May 8, 2023 3:00 pmTesting tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.
In an
Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations
April 5, 2023 4:55 pmby Nichole Tucker
The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting … Read more
Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer
March 27, 2023 9:13 amby Devin McLaughlin
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers observed favorable surgical outcomes — even … Read more
Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
March 27, 2023 9:11 amby Jason Harris
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1… Read more
Genetic Test Identifies Ovarian Cancer Patients Likely To Benefit From PARP Inhibitors
January 12, 2023 9:58 amA genetic test developed in a study at the University of Helsinki and Helsinki University Hospital identifies ovarian cancer patients who benefit from PARP inhibitors, a treatment option.
Since the therapy is associated with potential serious side-effects, it is important … Read more
FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer
November 18, 2022 11:51 amby Jason Harris
The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1
The company is considering the FDA’s request. If the 2 sides
FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer
November 14, 2022 11:41 amby Kristi Rosa
At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA
Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial
October 27, 2022 2:26 pmBarcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.
Presenting results from the … Read more
Elizabeth Swisher, MD, on Predicting Therapy Benefits in Ovarian Cancer
October 5, 2022 4:42 pmby Mark L. Fuerst
– KELIM score can now be used to look at upfront response, study showed
Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more
ASCO Addresses PARP Controversy in Guideline Update
September 28, 2022 12:01 pm— A response to “practice-changing data” in the first- and second-line setting
by Mike Bassett
Maintenance Therapy the ‘Biggest Breakthrough in Decades’ for Ovarian Cancer
September 15, 2022 1:54 pmby Karen Blum
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,
Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer
September 15, 2022 10:45 amby Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials
September 9, 2022 10:37 amby Mike Bassett
— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more